BRPI0513858A - compostos de benziltriazolona como inibidores não-nucleosìdeos da transcriptase reversa - Google Patents

compostos de benziltriazolona como inibidores não-nucleosìdeos da transcriptase reversa

Info

Publication number
BRPI0513858A
BRPI0513858A BRPI0513858-2A BRPI0513858A BRPI0513858A BR PI0513858 A BRPI0513858 A BR PI0513858A BR PI0513858 A BRPI0513858 A BR PI0513858A BR PI0513858 A BRPI0513858 A BR PI0513858A
Authority
BR
Brazil
Prior art keywords
benzyltriazolone
compounds
reverse transcriptase
transcriptase inhibitors
nucleoside reverse
Prior art date
Application number
BRPI0513858-2A
Other languages
English (en)
Inventor
James Patrick Dunn
Todd Richard Elworthy
Dimitrios Stefanidis
Zachary Kevin Sweeney
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of BRPI0513858A publication Critical patent/BRPI0513858A/pt
Publication of BRPI0513858B1 publication Critical patent/BRPI0513858B1/pt
Publication of BRPI0513858B8 publication Critical patent/BRPI0513858B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D249/12—Oxygen or sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

COMPOSTOS DE BENZILTRIAZOLONA COMO INIBIDORES NãO-NUCLEOSìDEOS DA TRANSCRIPTASE REVERSA. A presente invenção refere-se a um composto de acordo com a fórmula (I), aos métodos para tratar as doenças mediadas pelo vírus da imunodeficiência humana por administração de um composto de acordo com a fórmula (I) e às composições farmacêuticas para tratar as doenças mediadas pelo vírus da imunodeficiência humana, contendo um composto de acordo com a fórmula, onde R¬ 1¬, R¬ 2¬, R¬ 3¬, R¬ 4¬ R¬ 5¬ são como definidos aqui.
BRPI0513858A 2004-07-27 2005-07-20 compostos de benziltriazolona como inibidores não-nucleosídeos da transcriptase reversa, seu processo de preparação, seu uso e composição farmacêutica que os compreende BRPI0513858B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US59131104P 2004-07-27 2004-07-27
US60/591,311 2004-07-27
PCT/EP2005/007893 WO2006010545A1 (en) 2004-07-27 2005-07-20 Benzyltriazolone compounds as non-nucleoside reverse transcriptase inhibitors

Publications (3)

Publication Number Publication Date
BRPI0513858A true BRPI0513858A (pt) 2008-05-20
BRPI0513858B1 BRPI0513858B1 (pt) 2020-11-10
BRPI0513858B8 BRPI0513858B8 (pt) 2021-05-25

Family

ID=35056908

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0513858A BRPI0513858B8 (pt) 2004-07-27 2005-07-20 compostos de benziltriazolona como inibidores não-nucleosídeos da transcriptase reversa, seu processo de preparação, seu uso e composição farmacêutica que os compreende

Country Status (16)

Country Link
US (1) US7666891B2 (pt)
EP (1) EP1773790B1 (pt)
JP (1) JP4675959B2 (pt)
CN (1) CN1993332B (pt)
AR (1) AR050266A1 (pt)
AU (1) AU2005266530B2 (pt)
BR (1) BRPI0513858B8 (pt)
CA (1) CA2574308C (pt)
ES (1) ES2391461T3 (pt)
IL (1) IL180495A (pt)
MX (1) MX2007000788A (pt)
NO (1) NO338376B1 (pt)
RU (1) RU2394028C2 (pt)
SG (1) SG148179A1 (pt)
TW (1) TWI299334B (pt)
WO (1) WO2006010545A1 (pt)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR057455A1 (es) * 2005-07-22 2007-12-05 Merck & Co Inc Inhibidores de la transcriptasa reversa de vih y composicion farmaceutica
CN101291905A (zh) 2005-10-19 2008-10-22 弗·哈夫曼-拉罗切有限公司 苯乙酰胺nnrt抑制剂
CL2007002105A1 (es) * 2006-07-21 2008-02-22 Hoffmann La Roche Compuestos derivados de 2-[3-(3-cianofenoxi)(fenoxi o fenilsulfanil)]-n-fenil acetamida, inhibidores de la transcriptasa inversa del vih; procedimiento de preparacion; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar u
RU2451676C2 (ru) * 2006-08-16 2012-05-27 Ф.Хоффманн-Ля Рош Аг Ненуклеозидные ингибиторы обратной транскриптазы
TW200831085A (en) * 2006-12-13 2008-08-01 Merck & Co Inc Non-nucleoside reverse transcriptase inhibitors
WO2008119662A1 (en) 2007-03-29 2008-10-09 F. Hoffmann-La Roche Ag Non-nucleoside reverse transcriptase inhibitors
CN101679414A (zh) * 2007-04-09 2010-03-24 弗·哈夫曼-拉罗切有限公司 非核苷逆转录酶抑制剂
BR122021006634B1 (pt) * 2007-05-30 2022-03-29 F. Hoffmann-La Roche Ag Processo para preparação de triazolonas
JP5167350B2 (ja) 2007-05-30 2013-03-21 エフ．ホフマン−ラ ロシュ アーゲー 非ヌクレオシド系逆転写酵素阻害剤
JP2010530863A (ja) * 2007-06-22 2010-09-16 エフ．ホフマン−ラ ロシュ アーゲー 非ヌクレオシド逆転写酵素阻害剤としての尿素及びカルバマート誘導体
WO2009080534A1 (en) * 2007-12-21 2009-07-02 F. Hoffmann-La Roche Ag Heterocyclic antiviral compounds
US20090181068A1 (en) 2008-01-14 2009-07-16 Dunn Richard L Low Viscosity Liquid Polymeric Delivery System
CN101723909B (zh) * 2008-10-29 2011-12-28 天津药物研究院 三唑酮类化合物、其制备方法和用途
CN101735023B (zh) * 2008-11-24 2014-07-09 联化科技股份有限公司 一种3-溴-5-氯苯酚的制备方法
PT2501698T (pt) 2009-11-18 2018-07-23 Nat Res Council Canada Monómeros fluorados, oligómeros e polímeros para utilização em dispositivos eletrónicos orgânicos
CN102146022B (zh) * 2010-02-05 2013-07-03 中国中化股份有限公司 3-氯-5-溴苯酚的制备方法
EP2593419A1 (en) 2010-07-15 2013-05-22 Albemarle Corporation Processes for producing 4-bromo-2-methoxybenzaldehyde
BR112015005997A8 (pt) * 2012-09-26 2023-04-11 Merck Sharp & Dohme Composto
SG11201504622PA (en) 2012-12-20 2015-07-30 Inception 2 Inc Triazolone compounds and uses thereof
CN105579440A (zh) 2013-09-06 2016-05-11 因森普深2公司 三唑酮化合物及其应用
GB2598624A (en) * 2020-09-07 2022-03-09 Lorico Aurelio Use of triazole analogues for inhibition of a tripartite VOR protein complex in multicellular organisms

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3274185A (en) * 1963-10-08 1966-09-20 S E Massengill Company Phthalazine derivatives
US3813384A (en) * 1972-01-17 1974-05-28 Asta Werke Ag Chem Fab Basically substituted benzyl phthalazone derivatives,acid salts thereof and process for the production thereof
JP2593084B2 (ja) 1986-12-19 1997-03-19 メレルダウファーマスーティカルズ インコーポレーテッド ５−アリールー３ｈ−１，２，４−トリアゾールー３−オン類の神経変性障害の処置への用途
PH24094A (en) 1986-12-19 1990-03-05 Merrell Dow Pharma 5-aryl-3h-1,2,4-triazol-3-ones and their use as anticonvulsants
US5436252A (en) * 1986-12-19 1995-07-25 Merrell Dow Pharmaceuticals Inc. 5-aryl-3H-1,2,4-triazol-3-ones and their use in the treatment of neurodegenerative disorders
US4826990A (en) * 1987-09-30 1989-05-02 American Home Products Corporation 2-aryl substituted heterocyclic compounds as antiallergic and antiinflammatory agents
US4942236A (en) * 1987-09-30 1990-07-17 American Home Products Corporation 2-aryl substituted pyridyl-containing phenyl sulfonamido compounds as antiallergic and antiinflammatory agents
US5103014A (en) * 1987-09-30 1992-04-07 American Home Products Corporation Certain 3,3'-[[[(2-phenyl-4-thiazolyl)methoxy]phenyl]methylene]dithiobis-propanoic acid derivatives
US5331002A (en) * 1990-04-19 1994-07-19 Merrell Dow Pharmaceuticals Inc. 5-aryl-4-alkyl-3H-1,2,4-triazole-3-thiones useful as memory enhancers
US5922751A (en) * 1994-06-24 1999-07-13 Euro-Celtique, S.A. Aryl pyrazole compound for inhibiting phosphodiesterase IV and methods of using same
AU2381397A (en) 1996-04-19 1997-11-12 Novo Nordisk A/S Modulators of molecules with phosphotyrosine recognition units
TW467902B (en) 1996-07-31 2001-12-11 Bristol Myers Squibb Co Diphenyl heterocycles as potassium channel modulators
US6367003B1 (en) * 1998-03-04 2002-04-02 Micron Technology, Inc. Digital signal processor having enhanced utilization of multiply accumulate (MAC) stage and method
IT1305313B1 (it) * 1998-07-17 2001-05-04 Colla Paolo 3,4 - diidro- 6- benzil-4-oxopirimidine sostituite e relativo processodi produzione e impiego nella terapia delle infezioni da hiv-1.
UA82048C2 (uk) * 2000-11-10 2008-03-11 Эли Лилли Энд Компани Агоністи альфа-рецепторів, активованих проліфератором пероксисом
WO2002040021A2 (en) * 2000-11-17 2002-05-23 Idenix (Cayman) Limited Methods for inhibiting the transmission of hiv using topically applied substituted 6-benzyl-4-oxopyrimidines
TW200505441A (en) * 2003-03-24 2005-02-16 Hoffmann La Roche Non-nucleoside reverse transcriptase inhibitorsⅠ

Also Published As

Publication number Publication date
US20060025462A1 (en) 2006-02-02
CA2574308A1 (en) 2006-02-02
IL180495A0 (en) 2007-06-03
TWI299334B (en) 2008-08-01
AR050266A1 (es) 2006-10-11
RU2007106928A (ru) 2008-09-10
US7666891B2 (en) 2010-02-23
CN1993332B (zh) 2011-04-06
WO2006010545A1 (en) 2006-02-02
NO20070258L (no) 2007-01-15
TW200616979A (en) 2006-06-01
SG148179A1 (en) 2008-12-31
IL180495A (en) 2013-12-31
CN1993332A (zh) 2007-07-04
BRPI0513858B8 (pt) 2021-05-25
CA2574308C (en) 2014-03-25
EP1773790B1 (en) 2012-08-15
JP4675959B2 (ja) 2011-04-27
AU2005266530A1 (en) 2006-02-02
JP2008508211A (ja) 2008-03-21
RU2394028C2 (ru) 2010-07-10
NO338376B1 (no) 2016-08-15
AU2005266530B2 (en) 2012-04-12
MX2007000788A (es) 2007-03-23
BRPI0513858B1 (pt) 2020-11-10
ES2391461T3 (es) 2012-11-27
EP1773790A1 (en) 2007-04-18

Similar Documents

Publication Publication Date Title
BRPI0513858A (pt) compostos de benziltriazolona como inibidores não-nucleosìdeos da transcriptase reversa
EA200900066A1 (ru) Кристаллические сольваты и комплексы производных (1s)-1,5-ангидро-1-c-(3-((фенил)метил)фенил) -d-глюцитола с аминокислотами в качестве ингибиторов sglt2 для лечения диабета
EA201071045A1 (ru) Соединения оксадиазоантрацена для лечения диабета
UA117800C2 (uk) Похідні урацилу або тиміну для лікування гепатиту с
EA201190235A1 (ru) Замещенные 1-цианоэтилгетероциклилкарбоксамидные соединения 750
BRPI0610850A2 (pt) derivados de Ácido aril alquila, composiÇço farmacÊutica, medicamento, bem como uso dos referidos derivados
EA200970156A1 (ru) Пиридизиноновые производные
CY1117576T1 (el) Δινουκλεοτιδικα προφαρμακα
BR112013028430A2 (pt) composto, composição farmacêutica, método para tratar uma doença ou condição mediada por tirosina quinase do baço (syk), e, uso de uma quantidade terapeuticamente eficiente do composto
EA200700851A1 (ru) Получение и применение бифенил-4-илкарбониламинокислотных производных для лечения ожирения
EA201170772A1 (ru) Органические соединения
BRPI0818533B8 (pt) composto, composição farmacêutica, uso de um composto, e, processo para a preparação de um composto
ATE517882T1 (de) Chinolinderivate
BRPI0819328A8 (pt) Compostos inibidores de replicação de vírus da imunodeficiência humana, composição farmacêutica e uso dos ditos compostos
BRPI0813244B8 (pt) compostos derivados de pirazinona, composições compreendendo ditos compostos, uso dos compostos no tratamento de doenças de pulmão e composto intermediário
BRPI0507198A (pt) derivados de bisariluréia
EA201100311A1 (ru) Амидные производные гетероарилов и их применение в качестве активаторов глюкокиназы
DE602007008616D1 (de) Verfahren zur herstellung von 4'-azidocytidinderivaten
CY1111327T1 (el) Υποκατεστημενα παραγωγα κυκλοεξυλοξεικου οξεος
BRPI0407591A (pt) inibidores de transcriptase reversa de não-nucleosìdeo
NO20076425L (no) Fremgangsmater for behandling av drug-resistent cancer
BRPI0408767A (pt) inibidores de transcriptase reversa não-nucleosìdeos i para o tratamento de doenças mediadas pelo hiv
EA201070442A1 (ru) НОВЫЕ ИНГИБИТОРЫ sEH И ИХ ПРИМЕНЕНИЕ
CY1109569T1 (el) Υποκατεστημενα παραγωγα κυκλοεξανο-1,4-διαμινης
BRPI0518096A (pt) composto, composição farmacêutica, uso de um composto para a preparação de um medicamento para o tratamento de uma condição resultante de uma anormalidade na produção de óxido nìtrico, uso de um composto para a preparação de um medicamento para o tratamento da dor em um indivìduo com necessidade do mesmo e uso de um composto para a preparação de um medicamento para o tratamento de inibição da dimerização de inos

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 10/11/2020, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 20/07/2005 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF